Overview
- Published in Science, the GLA-3M-052-LS+OVA formulation protected mice for at least three months from SARS‑CoV‑2 and other coronaviruses, Staphylococcus and Acinetobacter bacteria, and a house‑dust‑mite allergen.
- Experiments recorded a 100‑ to 1,000‑fold reduction in viruses reaching the lungs after dosing, with adaptive immune responses activating in about three days.
- The candidate mimics T‑cell cues to keep innate lung macrophages on alert while a harmless antigen recruits T cells to sustain the effect.
- Stanford researchers are seeking funding to begin a Phase I safety trial followed by controlled exposure studies, with availability estimated at five to seven years if development succeeds.
- Independent experts called the findings promising but cautioned that results are from mice and that sustained immune activation may carry safety risks or fail to translate to people.